Soleno - נכסים נקיים למניה בודדת SLNO

This daily price chart for Soleno Therapeutics (SLNO) shows quotes at 9.65. Current growth is hampered by geopolitical tensions, which complicate component imports and limit the scale of medical trials. The business relies on the development of DCCR, a unique treatment for Prader-Willi syndrome with exclusive status. All resources are currently focused on bringing this breakthrough metabolic product to market.

Book value per share is calculated as the difference between total assets and liabilities, divided by the number of outstanding shares. This metric determines the intrinsic value of an investor's stake, reflecting the actual capitalization of net assets. For Soleno Therapeutics (SLNO), this calculation is critical due to the development costs of the Prader-Willi syndrome therapy. The bps trend demonstrates capital resilience during the clinical trial period. Analysis of the bps metric allows for an assessment of the risk of frozen funds during a change in the market cycle.